An approximately $24,000 net increase in monthly subscription sales to date since November 2025Localizer adoption expands to 145 independent State Farm agencies, with additional sales growth outside State Farm agentsPartner campaigns are also now delivering measurable results in the home services sector, driving further sales growth PERTH, Australia, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Locafy Limited (Nasdaq: LCFY, LCFYW) (“Locafy” or the “Company”), a global software-as-a-service technology company specializ ...

Preliminary Phase 2 data demonstrate PCS6422+Capecitabine increased cancer-killing metabolite exposure while maintaining comparable safety to monotherapy capecitabine Company on track to conduct formal interim analysis in early 2026 VERO BEACH, Fla., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies, today provided a clinical update on its ongoing Phase 2 study of NGC-Cap, the combinat ...

ORANGE, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC), today announced that it will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, Jan. 14, at 10:30 a.m. PST A webcast and replay of the presentation will be available on Alignment’s investor relations website at https://ir.alignmenthealth.com/. About Alignment HealthcareAlignment Health is championing a new path in senior care that empowers members to age well and live their m ...

Phase 1 data confirms SAB-142 does not cause serum sickness and has low/no immunogenicity at any dose and in all cohorts, including redosed healthy volunteersStudy results support the chronic dosing of SAB-142 in an outpatient setting for the treatment of stage 3 autoimmune type 1 diabetesPhase 2b SAFEGUARD trial underway and recruiting at multiple sites around the world MIAMI, Dec. 17, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing h ...

Completion of DLT observation period for Cohort 1; first patient in Cohort 2 dosed at higher cell level; additional dosing in Cohort 1 SOUTH SAN FRANCISCO, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (OTCQB: CERO) (“CERo” or the “Company”), an innovative cellular immunotherapy company pursuing new targets and novel phagocytic mechanisms, announces recent advances to the CertainT-1 trial that is focused on patients with acute myeloid leukemia (AML). Following completion of the ...

VANCOUVER, British Columbia, Dec. 17, 2025 (GLOBE NEWSWIRE) -- SAGA Metals Corp. ("SAGA" or the "Company") (TSXV: SAGA) (OTCQB: SAGMF) (FSE: 20H), a North American exploration company advancing critical mineral discoveries, is pleased to announce the full logging of all eight drill holes completed in the Trapper zone and confirms shipping three additional holes to IGS’s lab for analysis. Additionally, important new structural data in Trapper South’s R-0014 have been identified, providing valuable insights i ...

The $5 million investment into MAX Power from a leading conglomerate in Vietnam has officially closed and launches an international collaboration focused on accelerating Natural Hydrogen development in Saskatchewan, positioning Canada at the forefront of a new clean energy frontier. Video: Lawson – Canada’s First Big Step into Natural Hydrogen https://www.youtube.com/watch?v=lTTOwMxz_zo SASKATOON, Saskatchewan, Dec. 17, 2025 (GLOBE NEWSWIRE) -- MAX Power Mining Corp. (CSE: MAXX; OTC: MAXXF; FRANKFURT: 89N) ...

ROCKVILLE, Md. and SUZHOU, China, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced today that the Company’s management plans to present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. T ...

Minneapolis, MN, Dec. 17, 2025 (GLOBE NEWSWIRE) -- SharpLink Gaming, Inc. (Nasdaq: SBET) (“SharpLink” or the “Company”), one of the world’s largest corporate holders of Ether (“ETH”) and prominent industry advocate of Ethereum adoption, today announced that effective December 15, 2025 its Board of Directors has appointed Joseph Chalom as sole Chief Executive Officer and elected him to the Board. Rob Phythian has stepped down from his roles as Co-Chief Executive Officer and Director, marking the completion o ...

Following closing, combined company plans to progress Yarrow’s lead program, YB-101, a potentially first-in-class anti-thyroid-stimulating hormone receptor (“TSHR”) antibody for Graves’ disease (“GD”) and thyroid eye disease (“TED”)Yarrow Bioscience is the seventh biotechnology company founded by RTW Investments and plans to advance in-licensed asset YB-101 (also known as GS-098) into a U.S.-based Phase 1b/2b trial in patients with GD in the first half of 2026; a Phase 1 trial in TED is being conducted in C ...